Ongoing Monoclonal Antibodies and Plasmids Services through GENSCRIPT
ID: NOI-NIAID-25-2253129Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIAIDBETHESDA, MD, 20892, USA

NAICS

Testing Laboratories and Services (541380)

PSC

MEDICAL- LABORATORY TESTING (Q301)
Timeline
    Description

    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), intends to negotiate a sole-source contract with GenScript USA Inc. for ongoing monoclonal antibodies and plasmids services. The procurement aims to support the NIAID Laboratory of Immunogenetics (LIG) in advancing research on human B cells and the isolation of monoclonal antibodies, which are critical for developing new vaccine candidates against influenza. This contract is a continuation of existing services that require continuity for accurate comparison of results, and interested parties may submit capability statements via the NIAID electronic Simplified Acquisition Submission System (eSASS) by January 3, 2025, at 5:00 PM ET. For further inquiries, contact Dana Monroe at dana.monroe@nih.gov or call 406-375-9814.

    Point(s) of Contact
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Similar Opportunities
    In Vitro Biological Reagents
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), intends to negotiate a sole source procurement with Becton, Dickinson and Company for various in vitro biological reagents essential for research purposes. The procurement includes specific quantities of antibodies and reagents, such as Hu CD183 BV711 and Hu IL-13 BV421, along with shipping and handling to be delivered to Gaithersburg, Maryland. This procurement is justified under the authority of 41 U.S.C. 1901 (a)(1), indicating that only one responsible source can meet the agency's requirements. Interested parties may submit a capability statement via the NIAID electronic Simplified Acquisition Submission System (eSASS) by December 30, 2024, with all submissions considered at the Government's discretion. For further inquiries, contact Leah Hinson at leah.hinson@nih.gov.
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    65--Illumina Reagents and Consumables
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Heart, Lung, and Blood Institute (NHLBI), intends to award a non-competitive contract to Illumina, Inc. for the supply of "Illumina Reagents and Consumables" essential for various sequencing and genotyping systems. This procurement is driven by the unique operational needs of NIH-owned systems, as confirmed by market research indicating that only Illumina can provide the proprietary reagents necessary to maintain research integrity and support ongoing studies. The contract performance period is set from September 3, 2025, to September 2, 2030, and interested parties may submit capability statements for review by January 6, 2025; however, this is not a solicitation for proposals. For further inquiries, interested parties can contact Ethan J. Mueller at ethan.mueller@nih.gov or by phone at +1 301 496 2153.
    CHROMIUM IX/X AND VISIUM CYTASSIT ASSURANCE PLAN
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking to negotiate a sole-source contract with 10X Genomics, Inc. for a warranty and maintenance agreement for their Chromium X and CytAssist instruments. This procurement is critical as these instruments are essential for conducting advanced single-cell sequencing and spatial transcriptomics research, which supports the development of new diagnostics, therapeutics, and vaccines against human diseases. The maintenance agreement will ensure uninterrupted operation of these technologies, which are vital for NIAID researchers, and interested vendors must submit their capabilities statements via the NIAID electronic Simplified Acquisition Submission System (eSASS) by 12:00 PM EST on December 30, 2024. For further inquiries, vendors can contact Maliaka Pinkney at maliaka.pinkney@nih.gov or Jesse D. Weidow at weidowjd@niaid.nih.gov.
    Cytiva Sefia S-2000 Cell Processing Instrument Preventative Maintenance Services
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH) intends to award a sole source contract to Global Life Sciences Solutions USA LLC for preventative maintenance services on three Cytiva Sefia S-2000 Cell Processing Instruments located at the NIH Clinical Center in Bethesda, Maryland. The contract will cover unlimited service repair and preventive maintenance for these critical instruments used in cell therapy manufacturing and research, which are essential for compliance with FDA regulations regarding the maintenance of equipment used in drug product manufacturing. Interested parties capable of providing similar services may submit a capability statement by December 29, 2024, at 12:00 pm EST to Sheri Eiri at sheri.eiri@nih.gov for consideration in the procurement process.
    Global Life Sciences Solutions Preventative Maintenance Services
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a sole-source contract for preventative maintenance services for three Sepax Pro Cell Processing Systems used in cell therapy manufacturing and research. The contract will be awarded to Global Life Sciences Solutions USA LLC, the only vendor authorized to perform these services due to the proprietary nature of the equipment and the requirement for compliance with FDA regulations regarding critical equipment maintenance. The period of performance for this contract is set from January 27, 2025, to January 26, 2026, with interested parties encouraged to submit capability statements by December 28, 2024, to Sheri Eiri at sheri.eiri@nih.gov for consideration.
    Orbitor RS2 Microplate Robotic Bundle with Software
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through its National Institute of Allergy and Infectious Diseases (NIAID), intends to procure an Orbitor RS2 Microplate Robotic Bundle with integrated software for its Vaccine Immunology Program (VIP) within the Vaccine Research Center (VRC). This procurement aims to automate the handling and analysis of Mabtech Fluorospot Assays, which are critical for evaluating T-cell responses in clinical trials, thereby enhancing the efficiency and accuracy of vaccine research. The equipment must meet specific technical requirements, including compatibility with existing lab systems and advanced features such as a bi-directional telescoping arm and Momentum™ scheduling software. Interested vendors are invited to submit capability statements via the NIAID electronic Simplified Acquisition Submission System (eSASS) by January 3, 2025, at 5:00 PM ET, with all submissions considered by the Government at its discretion.
    SERVICE AGREEMENT FOR THERMO ELECTRON LABORATORY EQUIPMENT (AMBIS 2247584)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting quotes for maintenance agreements on Thermo Electron laboratory equipment, critical for research involving complex proteomic data. The procurement, identified by solicitation number RFQ-NIAID-25-2247584, requires comprehensive service plans for various mass spectrometry instruments, ensuring prompt maintenance response times, priority technical support, and regular preventive maintenance visits. This equipment is essential for analyzing high-value samples in ongoing research projects, and the contract period spans from March 19, 2025, to March 18, 2026. Interested vendors must submit their quotes electronically by December 30, 2024, and can contact Kimberly Rubio at kimberly.rubio@nih.gov for further information.
    Support Plan for a Stellaris 8 Confocal Microscope (S/N 8300000444)
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), intends to negotiate a sole-source contract with Leica Microsystems Inc. for a 12-month renewal Support Plan for a Stellaris 8 Confocal Microscope (S/N 8300000444), with two optional one-year extensions. The procurement aims to secure a comprehensive maintenance agreement that includes unlimited service visits by trained engineers, OEM replacement parts, annual planned maintenance, and access to expert support, ensuring the microscope operates at optimal performance levels. This equipment is crucial for research and diagnostics in the field of allergy and infectious diseases, highlighting the importance of maintaining its functionality. Interested vendors must submit capability statements by 10:00 AM EST on December 30, 2024, through the NIAID electronic Simplified Acquisition Submission System (eSASS), with all required documentation to be included for consideration.
    National Institute of Environmental Health Sciences (NIEHS) Assessment of Immunotoxicity – In Vitro and In Vivo Assessment of Immune Function
    Active
    Health And Human Services, Department Of
    The National Institute of Environmental Health Sciences (NIEHS), part of the Department of Health and Human Services, is seeking proposals for a federal contract focused on the assessment of immunotoxicity through in vitro and in vivo evaluation of immune function. The objective is to provide comprehensive research services to evaluate how selected test agents may modulate immune responses, utilizing both established and innovative methodologies to reduce animal use in toxicology studies. This contract, anticipated to be a cost-plus-fixed-fee type, is expected to be awarded by September 2025, with a base period of one year and nine optional one-year extensions. Interested parties should direct inquiries to Adam Muhsin at adam.muhsin@nih.gov and monitor the Sam.gov website for the solicitation release, which is expected no sooner than 15 days from this notice.